These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 17315162)

  • 1. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
    Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
    J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
    Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
    Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    D'Amico AV; Renshaw AA; Loffredo B; Chen MH
    Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
    Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
    D'Amico AV; Chen MH; Catalona WJ; Sun L; Roehl KA; Moul JW
    Cancer; 2007 Jul; 110(1):56-61. PubMed ID: 17530618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
    D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
    Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
    Alexander BM; Chen MH; Carroll P; D'Amico AV
    Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
    D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
    J Urol; 2005 May; 173(5):1572-6. PubMed ID: 15821488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
    Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.